News Article,Video
Maple Grove Medical Device Company Shares How They are Surviving During COVID-19
October 5, 2020
CCX Media visited Francis Medical on September 30, 2020, to interview President and CEO Mike Kujak, and get an inside look at how we’re thriving and moving forward during the COVID-19 pandemic, including a $4M investment from world-renown urology company, Coloplast. (2 1/2 min video)
Recent Posts
Francis Medical Announces Further Expansion of Commercial Vanquish® Procedures to Ablate Prostate Tissue
websites2026-05-06T13:39:18-05:00May 6th, 2026|
Minneapolis [May 06, 2026] – Francis Medical, Inc., a privately held medical device company based in Maple Grove, Minn., today announced that Naveen Kella, MD, of The Urology Place has successfully completed the first commercial procedures in San Antonio, Texas, using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue. Dr. Kella, who was also a clinical investigator in the VAPOR 2 pivotal study, performed the procedures on patients diagnosed with localized prostate cancer at Huebner Ambulatory Surgery Center.
Francis Medical Announces First Commercial Vanquish® Procedure to Ablate Prostate Tissue in the Midwest
websites2026-04-20T17:16:40-05:00April 21st, 2026|
Minneapolis [April 21, 2026] – Francis Medical, Inc., a privately held medical device company based out of Maple Grove, MN, today announced that Aaron Milbank, MD. of Minnesota Urology has successfully completed the first commercial procedure in the Midwest using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue.
Francis Medical Announces Further Commercial Expansion of Vanquish® Water Vapor Ablation with First Commercial Procedures to Ablate Targeted Prostate Tissue in the Southeast
websites2026-04-16T08:53:16-05:00April 16th, 2026|
Minneapolis, MN [April 16, 2026] – Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the first commercial procedures performed using the Vanquish® Water Vapor Ablation System in the Southeast, a minimally invasive technology designed to ablate targeted prostate tissue.





Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.